This technology is a multiplex, array-based serologic assay for the rapid diagnosis of tick-borne illnesses, adaptable to other formats such as a lateral flow device.
Current methods to diagnose tick-borne diseases (TBDs) consist of multi-step, labor-intensive laboratory methods that measure protein concentrations in serologic samples. However, these approaches are limited in accuracy and sensitivity, often leading to false positives, and fail to diagnose early-stage tick-borne illnesses.
TBD-Serochip is a programmable peptide microarray platform that can detect antigenic targets from prominent agents of TBDs in a rapid and accurate manner. An array of up to 172,000 target peptides generates a comprehensive antigenic profile from the most prominent TBD agents. Fabrication of the array with semiconductor printing technology enables continuous and affordable modifications for specific needs. As such, this technology has the potential to streamline the diagnosis of TBDs, thereby enabling novel insights into the pathology and epidemiology of TBDs.
This technology has been validated with human serum samples.
Patent Pending (US20200255889)
Patent Pending (WO/2019/060885)
IR CU17323, CU19325
Licensing Contact: Kristin Neuman